The influence of TKI therapy on EGFR mutations status.
收藏NIAID Data Ecosystem2026-03-10 收录
数据链接：
官方服务：
资源简介：
The influence of TKI therapy on EGFR mutations status.
应用场景：
创建时间：
2017-03-24
相关数据集
Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer
Small cell lung cancer (SCLC) is an aggressive disease, with patients diagnosed with either early-stage, limited stage, or extensive stage of SCLC tumor progression. Discovering and targeting the func
NIAID Data Ecosystem110
Available IPD datapackage for study 'LUX-Lung 6: A Randomized, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation'
To investigate the efficacy and safety of BIBW 2992 compared to standard first-line chemotherapy in patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation
DataCite Commons2024-12-02 更新50
Design, Synthesis, and Biological Evaluation of Novel Orally Available Covalent CDK12/13 Dual Inhibitors for the Treatment of Tumors
Cyclin-dependent kinases 12 and 13 (CDK12/13) safeguard genomic integrity by preferentially regulating gene expression in the DNA damage response (DDR). The CDK12/13-mediated upregulation of DDR genes
NIAID Data Ecosystem10
Disease control rate at 3 months according to InVisionFirst results in 82 patients receiving FDA-approved targeted therapies.
Disease control rate at 3 months according to InVisionFirst results in 82 patients receiving FDA-approved targeted therapies.
Figshare2020-06-11 更新70
Chemotherapy plus EGFR-TKI as first-line treatment provides better survival for advanced EGFR positive lung adenocarcinoma patients: updated data and exploratory in vitro study
Chemotherapy plus EGFR-TKI as first-line treatment provides better survival for advanced EGFR positive lung adenocarcinoma patients: updated data and exploratory in vitro study
ChEBI2020-03-12 更新30
